top of page

Search Results

Results found for "Domain Therapeutics"

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    as decision trees and support vector machines which require handcrafted feature engineering, where domain revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively activate therapeutically analyzing drug-target interactions and disease pathways, AI can identify potential candidates that may have therapeutic

  • đŸ€ŻMind-blowing GPCR Scoops! Discover the Latest Breakthroughs! ⊿ Nov 18 - 24, 2024

    anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR Lior Peri ,  Donna Matzov ,  Dominic 2025 Milestones Recursion and Exscientia have merged to enhance drug discovery GPCR Classes Pathios Therapeutics Basic and Clinical Pharmacology GPCR Jobs NEW Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

  • Design and validation of recombinant protein standards for quantitative Western blot analysis of...

    context due to the low solubility that the hydrophobic nature imprinted by their seven transmembrane domains

  • Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⊿ Oct 28 - Nov 3, 2024

    et al. for their fantastic review on Molecular and structural insights into the 5-HT2C receptor as a therapeutic IPO to $331m Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR- Targeted Antibody Therapeutics Using Generative AI Zombie Fungi Hijack Hosts’ Brains GPCR Therapeutics, Inc. has received Orphan Drug 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic proteins in obesity and diabetes mellitus Molecular and structural insights into the 5-HT2C receptor as a therapeutic

  • Allosteric Binding Demystified: Smarter GPCR Drug Discovery

    Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa Therapeutics Premium delivers clarity where noise dominates.  

  • Structural landscape of the Chemokine Receptor system

    Data Bank (PDB) which reveal common structural features, such as the presence of seven transmembrane domains The N-terminal domains of CKRs has multiple sites for post-translational modifications, including tyrosine binding and receptor activation will pave the way for significant advancements in the development of therapeutics

  • Latrophilin-1 drives neuron morphogenesis and shapes chemo- and mechanosensation-dependent ...

    in the nematode Caenorhabditis elegans can also function independently of their seven-transmembrane domain

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic

  • GPCR Happy Hour Boston 2026 — April 29 | Dr. GPCR Community Event

    Whether you're decoding signaling pathways or designing the next generation of therapeutics, Revvity includes over 1,000 functional assays representing more than 550 GPCR and other targets, trusted by therapeutic

  • Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success

    That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic More nuanced control, fewer off-target liabilities, and novel therapeutic windows. Correctly distinguishing these mechanisms helps refine therapeutic index calculations, prioritize safer

  • Sweet taste receptor agonists attenuate macrophage IL‐1ÎČ expression and eosinophilic inflammation...

    Eosinophilic inflammation is a hallmark of refractory chronic rhinosinusitis (CRS) and considered a major therapeutic (ECRS) via macrophage IL‐1ÎČ overproduction, thereby suggesting autophagy regulation as a potential therapeutic We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related Methods We investigated the therapeutic effects of trehalose and saccharin on macrophage IL‐1ÎČ production

  • Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did

    Advances in biased signaling, allosterism, and endosomal signaling have opened new therapeutic frontiers

  • Illuminating C5aR Biology: The Role of Fluorescent Ligands in GPCR Research

    GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry molecular binding mechanism behind C5a and C5aR interaction is crucial for developing novel immunological therapeutics fluorescent probes have proven to be optimal tools to perform fluorescence-based assays to unlock the therapeutic Function, Structure and Therapeutic Potential of Complement C5a Receptors.

  • From Ox Liver to AI: How the History of Pharmacology Shapes Its Future

    👉 Join Terry’s Corner, your essential launchpad into the world of therapeutic science Unlock "The History

  • 📰 GPCR Weekly News, June 12 to 18, 2023

    GPCRs in Neuroscience Orphan receptor GPR88 as a potential therapeutic target for CNS disorders - an Industry News Coherus to Acquire Surface Oncology Confo Therapeutics and AbCellera partner on GPCR-targeting Patent in Japan Proteros Biostructures GmbH Revolutionizes Metabolic Disorder Treatments Structure Therapeutics (June 28 - 30, 2023) NEW FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

  • Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization

    Industry insights:  Fresh selectivity datasets on openMe; Novo’s obesity dominance faces new challengers Separate effect size from time:  Use allosteric modulators to expand therapeutic index and reduce overdose Why It Matters In the CNS, where receptor localization and real-time signaling shape therapeutic outcomes

  • Effects of Small Molecule Ligands on ACKR3 Receptors

    receptors, revealing a key role for the deeper binding pocket composed of residues in the transmembrane domains

  • GPCR Happy Hour – Boston, Sept 2025

    delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing therapeutics comprehensive approach enables Axxam to support clients worldwide in identifying and optimizing new therapeutic

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • When the Assay Says Nothing, Look Again: Kinetic Detection of Multi-Target GPCR Activity

    through: Why certain disease architectures require multi-target engagement in the first place, and the therapeutic across GLP-1, GIP, and glucagon receptor types The two-edged character of multi-target engagement: why therapeutic

  • GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!

    Receptor Bryan Roth  and Brian Krumm  for their excellent study on Molecular glues as potential GPCR therapeutics November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

  • 📰 GPCR Weekly News, May 8 to 14, 2023

    2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Research Council (ERC) Addex Reports Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, July 1 to 7, 2024

    September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    Modeling tools to understand how restricted diffusion  in tissues like tumors slows offset and improves therapeutic drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic

  • 📰 GPCR Weekly News, October 2 to 8, 2023

    This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

  • How Fast Does a Drug Work?

    essential for pipeline efficiency: How fast a ligand binds (k₁) and how long it stays bound (k₂)  can alter therapeutic When does onset rate dictate therapeutic onset, and when does offset rate predict duration?

  • 📰 GPCR Weekly News, September 11 to 17, 2023

    Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the ÎČ-adrenergic receptor

bottom of page